Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

REPLReplimune, Inc.Running, no new patients

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Non-Small Cell Lung Cancer (NSCLC) · Microsatellite Instability-High (MSI-H) · Non-melanoma Skin Cancer (NMSC) · Cutaneous Melanoma

4Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 4 insiders sold shares within a month

    Since Aug 17, 2026 · was worth 10, fading over time

    +3.9
Worry score4

Score over time

Stage
Phase 2
Patients
340 (planned)
Started
Sep 20, 2017
Main results expected
Jun 2028
Fully finished
Dec 2028
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Percentage of adverse events (AEs)

    Measured over: 26 months

  • Percentage of serious adverse events (SAEs)

    Measured over: 26 months

  • Percentage of dose limiting toxicities (DLTs)

    Measured over: 26 months

  • Percentage of overall response rate (ORR)

    Measured over: 26 months

  • Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RP1

    Measured over: 20 weeks

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 10, now 3.9, since 2026-08-17, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT03767348 · record last updated 2026-02-13 · checked 2026-11-09 15:36 UTC

See the official record on ClinicalTrials.gov (NCT03767348) ↗